In Cyvex Nutrition’s newest Vine newsletter, the company highlights a lesser-known omega-3 fatty acid, docosapentaenoic acid (DPA), and its newest weight management ingredient, SolaThin.
In Cyvex Nutrition’s newest Vine newsletter, the company highlights a lesser-known omega-3 fatty acid, docosapentaenoic acid (DPA), and its newest weight management ingredient, SolaThin.
Dubbed “the missing link,” DPA is described as an intermediary between two more popular omega-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Cyvex reports that DPA can potentially reduce the risk of acute coronary events in clinical trials, protect against age-related cognitive decline, and support lipid metabolism.
“Emerging evidence now seems to indicate DPA plays a substantial role in nutritional supplementation, as it has therapeutic potential to work synergistically with EPA and DHA as a stand-alone fatty acid,” says Cyvex.
Meanwhile, Cyvex is also promoting its SolaThin pure potato protein extract. SolaThin contains a special protein called protease inhibitor PI-2, which research indicates has the ability to produce cholecystokinin, a peptide believed to produce feelings of gastric fullness.
According to Cyvex, PI-2 is backed by 20 years of university research. Clinical trials suggest that SolaThin, via PI-2, can reduce food consumption by as much as 20%.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
2 Commerce Drive
Cranbury, NJ 08512